Literature DB >> 19521352

Lipid-induced insulin resistance is associated with increased monocyte expression of scavenger receptor CD36 and internalization of oxidized LDL.

Sangeeta R Kashyap1, Adriana G Ioachimescu, Heather L Gornik, Thottathil Gopan, Michael B Davidson, Antonie Makdissi, Jennifer Major, Maria Febbraio, Roy L Silverstein.   

Abstract

Elevated free fatty acids (FFAs) contribute to the development of insulin resistance, type 2 diabetes mellitus (T2DM), and may be atherogenic. We tested the relationship among lipid-induced insulin resistance, endothelial dysfunction, and monocyte capacity to form foam cells through scavenger receptor A (SRA) and CD36. Ten healthy subjects underwent 24-h infusion of Intralipid/heparin and saline (0.5 ml/min) on two separate occasions followed by brachial artery reactivity testing and a euglycemic hyperinsulinemic (80 mU/(kg.min)) clamp study to determine insulin sensitivity. Isolation of blood monocytes was performed 24 h after infusion. Surface expression and function of CD36 and SRA to take up oxidized low-density lipoprotein (oxLDL) was determined by flow cytometry and quantitative confocal imaging. Lipid infusion resulted in a twofold increase in serum FFA levels, reduced whole-body glucose disposal by approximately 20% (P < 0.05), and possibly impaired endothelial-dependent vasodilation (P = 0.1). Blood monocytes obtained during lipid infusion demonstrated a approximately 25% increase in cell surface expression of CD36 (P < 0.05) but no change in SRA expression. Enhanced CD36 expression was associated with a 50% increase in internalization of oxLDL (P < 0.05). The increase in CD36 surface expression during lipid infusion correlated inversely with glucose disposal (P < 0.05) and not with FFA levels or brachial artery dilation. These data support a role for FFAs in induction of insulin resistance and provide a link to atherogenic mechanisms mediated by expression of scavenger receptor CD36.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19521352      PMCID: PMC2836489          DOI: 10.1038/oby.2009.179

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  39 in total

Review 1.  CD36 and atherosclerosis.

Authors:  R L Silverstein; M Febbraio
Journal:  Curr Opin Lipidol       Date:  2000-10       Impact factor: 4.776

2.  A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation.

Authors:  E Griffin; A Re; N Hamel; C Fu; H Bush; T McCaffrey; A S Asch
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

3.  Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction.

Authors:  Stephen J Nicholls; Zeneng Wang; Robert Koeth; Bruce Levison; Brian DelFraino; Vladimir Dzavik; Owen W Griffith; David Hathaway; Julio A Panza; Steven E Nissen; Judith S Hochman; Stanley L Hazen
Journal:  Circulation       Date:  2007-10-29       Impact factor: 29.690

4.  Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.

Authors:  Dorte Glintborg; Kurt Højlund; Marianne Andersen; Jan Erik Henriksen; Henning Beck-Nielsen; Aase Handberg
Journal:  Diabetes Care       Date:  2007-11-13       Impact factor: 19.112

5.  Insulin acutely upregulates protein expression of the fatty acid transporter CD36 in human skeletal muscle in vivo.

Authors:  E Corpeleijn; M M A L Pelsers; S Soenen; M Mensink; F G Bouwman; M E Kooi; W H M Saris; J F C Glatz; E E Blaak
Journal:  J Physiol Pharmacol       Date:  2008-03       Impact factor: 3.011

Review 6.  The insulin resistance syndrome: physiological considerations.

Authors:  Sangeeta R Kashyap; Ralph A Defronzo
Journal:  Diab Vasc Dis Res       Date:  2007-03       Impact factor: 3.291

7.  Cd36, a class B scavenger receptor, functions as a monomer to bind acetylated and oxidized low-density lipoproteins.

Authors:  Catherine A Martin; Emma Longman; Carol Wooding; Sarah J Hoosdally; Saira Ali; Timothy J Aitman; Daniel A P Gutmann; Paul S Freemont; Bernadette Byrne; Kenneth J Linton
Journal:  Protein Sci       Date:  2007-09-28       Impact factor: 6.725

8.  Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils.

Authors:  Guohong Li; Alison C Keenan; Justin C Young; Margaret J Hall; Zehra Pamuklar; E Magnus Ohman; Steven R Steinhubl; Susan S Smyth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-05-24       Impact factor: 8.311

9.  Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion.

Authors:  E Nisoli; M O Carruba; C Tonello; C Macor; G Federspil; R Vettor
Journal:  Diabetes       Date:  2000-03       Impact factor: 9.461

10.  Hyperinsulinemia induces insulin resistance on glucose and lipid metabolism in a human adipocytic cell line: paracrine interaction with myocytes.

Authors:  Sonia Fernández-Veledo; Iria Nieto-Vazquez; Javier de Castro; M Pilar Ramos; Silke Brüderlein; Peter Möller; Margarita Lorenzo
Journal:  J Clin Endocrinol Metab       Date:  2008-04-22       Impact factor: 5.958

View more
  23 in total

1.  Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques.

Authors:  Shijie Li; Paul Kievit; Anna-Karin Robertson; Ganesh Kolumam; Xiumin Li; Karin von Wachenfeldt; Christine Valfridsson; Sherry Bullens; Ilhem Messaoudi; Lindsay Bader; Kyra J Cowan; Amrita Kamath; Nicholas van Bruggen; Stuart Bunting; Björn Frendéus; Kevin L Grove
Journal:  Mol Metab       Date:  2013-06-11       Impact factor: 7.422

Review 2.  CD36 genetics and the metabolic complications of obesity.

Authors:  Latisha Love-Gregory; Nada A Abumrad
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-11       Impact factor: 4.294

3.  Oxidized high-density lipoprotein impairs endothelial progenitor cells' function by activation of CD36-MAPK-TSP-1 pathways.

Authors:  Jianxiang Wu; Zhiqing He; Xiang Gao; Feng Wu; Ru Ding; Yusheng Ren; Qijun Jiang; Min Fan; Chun Liang; Zonggui Wu
Journal:  Antioxid Redox Signal       Date:  2014-12-02       Impact factor: 8.401

4.  CD36 genotype associated with ischemic stroke in Chinese Han.

Authors:  Yong Zhang; Jing Zang; Bin Wang; Bin Li; Xiaomei Yao; Hongyan Zhao; Wei Li
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  CD36 binds oxidized low density lipoprotein (LDL) in a mechanism dependent upon fatty acid binding.

Authors:  Anthony G Jay; Alexander N Chen; Miguel A Paz; Justin P Hung; James A Hamilton
Journal:  J Biol Chem       Date:  2015-01-01       Impact factor: 5.157

6.  Variants of the CD36 gene and metabolic syndrome in Boston Puerto Rican adults.

Authors:  Sabrina E Noel; Chao-Qiang Lai; Josiemer Mattei; Laurence D Parnell; Jose M Ordovas; Katherine L Tucker
Journal:  Atherosclerosis       Date:  2010-02-18       Impact factor: 5.162

Review 7.  The endocrinology of taste receptors.

Authors:  Sara Santa-Cruz Calvo; Josephine M Egan
Journal:  Nat Rev Endocrinol       Date:  2015-02-24       Impact factor: 43.330

8.  Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile.

Authors:  Latisha Love-Gregory; Richard Sherva; Timothy Schappe; Jian-Shen Qi; Jennifer McCrea; Samuel Klein; Margery A Connelly; Nada A Abumrad
Journal:  Hum Mol Genet       Date:  2010-10-08       Impact factor: 6.150

9.  Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress.

Authors:  Roy L Silverstein
Journal:  Clin Lipidol       Date:  2009-12

10.  Monocyte phenotyping and management of lipoprotein X syndrome.

Authors:  Zeqin Lian; Anum Saeed; Xueying Peng; Xiaoyuan Dai Perrard; Xiaoming Jia; Aliza Hussain; Christie M Ballantyne; Huaizhu Wu
Journal:  J Clin Lipidol       Date:  2020-09-04       Impact factor: 4.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.